Xilda 50mg Tablet contains Vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting the DPP-4 enzyme, Vildagliptin enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Xilda 50mg is typically prescribed as an adjunct to diet and exercise to improve blood sugar levels in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas. The tablet should be taken orally, once or twice daily, as directed by a healthcare professional. It is generally well tolerated, with a low risk of hypoglycemia when used as monotherapy. Common adverse effects may include headache, dizziness, or gastrointestinal disturbances. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Xilda 50mg is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose levels and renal function is recommended during therapy to ensure efficacy and safety. This medication should be used under medical supervision as part of a comprehensive diabetes management plan.